Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension.

Autor:	Schutte AE; School of Population Health, University of New South Wales, Kensington Campus, High Street, Sydney 2052 NSW, Australia; The George Institute for Global Health, King Street, Newton, Sydney NSW 2052, Australia.; Hypertension in Africa Research Team, SAMRC Unit for Hypertension and Cardiovascular Disease; North-West University, Hoffman Street, Potchefstroom 2520, South Africa.; SAMRC Development Pathways for Health Research Unit, School of Clinical Medicine, University of the Witwatersrand, 1 Jan Smuts Ave, Braamfontein, Johannesburg, 2000, South Africa., Jafar TH; Program in Health Services and Systems Research, Duke-NUS Medical School, Department of Renal Medicine, 8 College Rd., Singapore 169857, Singapore.; Duke Global Health Institute, Duke University, 310 Trent Dr, Durham, NC 27710, USA., Poulter NR; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London W12 7RH, UK., Damasceno A; Faculty of Medicine, Eduardo Mondlane University, 3453 Avenida Julius Nyerere, Maputo, Mozambique., Khan NA; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Center for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada., Nilsson PM; Department of Clinical Sciences, Skane University Hospital, Lund University, Malmö, Sweden., Alsaid J; Ochsner Health System, New Orleans, Louisiana, USA.; Queensland University, Brisbane, Queensland, Australia., Neupane D; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA., Kario K; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan., Beheiry H; International University of Africa, Khartoum, Sudan., Brouwers S; Department of Cardiology, Cardiovascular Center Aalst, OLV Clinic Aalst, Aalst, Belgium.; Department of Experimental Pharmacology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium., Burger D; Kidney Research Centre, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada., Charchar FJ; Health Innovation and Transformation Centre, Federation University, Ballarat, Victoria, Australia.; Department of Physiology and Anatomy, University of Melbourne, Melbourne, Victoria, Australia., Cho MC; Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea., Guzik TJ; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK., Haji Al-Saedi GF; Baghdad College of Medicine, Baghdad, Iraq., Ishaq M; Pakistan Hypertension League, Karachi, Pakistan., Itoh H; Department of Endocrinology, Metabolism and Nephrology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8585, Japan., Jones ESW; Division of Nephrology and Hypertension, Groote Schuur Hospital and Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa., Khan T; Department of Public Health Medicine, University of Pretoria, Pretoria, South Africa., Kokubo Y; Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan., Kotruchin P; Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand., Muxfeldt E; University Hospital Clementino Fraga Filho, Hypertension Program, Universidade Federal do Rio de Janeiro, Brazil., Odili A; Circulatory Health Research Laboratory, College of Health Sciences, University of Abuja, Abuja, Nigeria., Patil M; Department of Nutrition and Dietetics, Asha Kiran JHC Hospital, Chinchwad, India., Ralapanawa U; Faculty of Medicine, University of Peradeniya, Kandy, Central Province, Sri Lanka., Romero CA; Renal Division, Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA., Schlaich MP; Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit and RPH Research Foundation, The University of Western Australia, Perth, Australia.; Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.; Department of Nephrology, Royal Perth Hospital, Perth, Western Australia, Perth, Western Australia, Australia., Shehab A; College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates., Mooi CS; Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia., Steckelings UM; Department of Cardiovascular & Renal Research, Institute of Molecular Medicine. University of Southern Denmark, Odense, Denmark., Stergiou G; Hypertension Centre STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece., Touyz RM; Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada., Unger T; CARIM - Cardiovascular Research Institute, Maastricht University, Maastricht, The Netherlands., Wainford RD; Department of Pharmacology & Experimental Therapeutics and the Whitaker, Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA., Wang JG; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Williams B; Institute of Cardiovascular Science, University College London (UCL), National Institute for Health Research (NIHR), UCL Hospitals Biomedical Research Centre, London, UK., Wynne BM; Department of Internal Medicine, Division of Nephrology & Hypertension, University of Utah, Salt Lake City, UT, USA., Tomaszewski M; Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK.; Manchester Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK.; Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Jazyk:	angličtina
Zdroj:	Cardiovascular research [Cardiovasc Res] 2023 Mar 31; Vol. 119 (2), pp. 381-409.
DOI:	10.1093/cvr/cvac130
Abstrakt:	Abstract: Raised blood pressure (BP) is the leading cause of preventable death in the world. Yet, its global prevalence is increasing, and it remains poorly detected, treated, and controlled in both high- and low-resource settings. From the perspective of members of the International Society of Hypertension based in all regions, we reflect on the past, present, and future of hypertension care, highlighting key challenges and opportunities, which are often region-specific. We report that most countries failed to show sufficient improvements in BP control rates over the past three decades, with greater improvements mainly seen in some high-income countries, also reflected in substantial reductions in the burden of cardiovascular disease and deaths. Globally, there are significant inequities and disparities based on resources, sociodemographic environment, and race with subsequent disproportionate hypertension-related outcomes. Additional unique challenges in specific regions include conflict, wars, migration, unemployment, rapid urbanization, extremely limited funding, pollution, COVID-19-related restrictions and inequalities, obesity, and excessive salt and alcohol intake. Immediate action is needed to address suboptimal hypertension care and related disparities on a global scale. We propose a Global Hypertension Care Taskforce including multiple stakeholders and societies to identify and implement actions in reducing inequities, addressing social, commercial, and environmental determinants, and strengthening health systems implement a well-designed customized quality-of-care improvement framework. Competing Interests: Conflict of interest: A.E.S. received speaker honoraria from different pharmaceutical companies and device manufacturers for work unrelated to this paper; P.M.N. has received speaker honoraria from different pharmaceutical companies. K.K. reports research grants from A&D, Omron Healthcare, Fukuda Denshi, Otsuka Pharmaceutical, Otsuka Holdings, CureApp, Sanwa Kagaku Kenkyusho, Daiichi Sankyo, Taisho Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Boehringer-Ingelheim Japan, Pfizer Japan, Fukuda Lifetec, Bristol-Myers Squibb, Mochida Pharmaceutical, Roche Diagnostics; and Consulting fees from A&D, JIMRO, Omron Healthcare, CureApp, Kyowa Kirin, Sanwa Kagaku Kenkyusho, Terumo, Fukuda Denshi, Mochida Pharmaceutical; and Honoraria from Idorsia, Omron Healthcare, Daiichi Sankyo, Novartis Pharma, Mylan EPD; and Participation in Advisory Board of Daiichi Sankyo, Novartis Pharma, Fukuda Denshi outside the submitted work. J.-G.W. reports having received lecture and consulting fees from Novartis, Omron, Servier, and Viatris. M.P.S. has received consulting fees, and/or travel and research support from Medtronic, Abbott, Metavention, ReCor, Novartis, Servier, Pfizer, and Boehringer-Ingelheim. E.S.W.J. has received honoraria from pharmaceutical companies for work unrelated to this publication. N.R.P. has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier), research projects, and staff (Servier, Pfizer) and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma, Pfizer, Glenmark Pharma, Alkem Lab, and Emcure India). He holds no stocks and shares in any such companies. This manuscript was handled by Guest Editor Thomas F. Lüscher (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu